Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma. The design intentionally uses GPC3 as the primary target anchor because GPC3 is the dominant HCC cell-therapy antigen in current clinical development, while adding B7-H3 to reduce antigen escape and to broaden coverage across tumor and tumor-microenvironment compartments. The study first evaluates safety and dose-limiting toxicities, then expands at the recommended phase 2 dose.

Trial Details

NCT ID
NCT07500220
Phase
PHASE1 / PHASE2
Sponsor
Beijing Biotech
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • EB-G3B7-NK dual-target CAR-NK cells
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Age 18 to 75 years.
  • Histologically or cytologically confirmed HCC, or radiologically diagnosed HCC with mandatory tissue confirmation of target expression before enrol…
  • Unresectable, locally advanced, or metastatic HCC not amenable to curative surgery, transplant, or further locoregional therapy; BCLC stage C, or s…
  • Disease progression on, intolerance to, or ineligibility for at least 1 prior standard systemic regimen.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →